Gilead Sciences GILD Other Liver Disease — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's other liver disease — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's other liver disease — total revenues?
- Gilead Sciences (GILD) reported other liver disease — total revenues of $114M in Q1 2026.
- How has Gilead Sciences's other liver disease — total revenues changed year-over-year?
- Gilead Sciences's other liver disease — total revenues decreased by 5.8% year-over-year, from $121M to $114M.
- What is the long-term trend for Gilead Sciences's other liver disease — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's other liver disease — total revenues has grown at a 25.1% compound annual growth rate (CAGR), from $426M to $834M.
- What does other liver disease — total revenues mean?
- The total sales revenue generated from the company's secondary liver disease therapeutic product line.
- How do you interpret other liver disease — total revenues?
- An increase indicates successful commercialization, market penetration, or expansion of the secondary liver disease product portfolio, while a decrease may signal market saturation, competitive pressure, or product lifecycle maturity.
- How does other liver disease — total revenues compare across companies?
- Comparable to secondary therapeutic segment revenues in other large-cap biopharmaceutical companies, often evaluated against the growth rates of primary core franchises to assess portfolio diversification.